Patent · US Active

Substituted 3-phenoxyazetidin-1-yl-pyrazines

US11780827B2 · kind B2 · utility

1Cited by

0References

11Claims

0Family size

Assignees

Boehringer Ingelheim International GmbH · DE
Arena Pharmaceuticals, Inc. · US

Inventors

Kai Gerlach · Biberach, DE
Graeme Semple · Mölndal, SE
Yifeng Xiong · San Diego, US
Barbara Bertani · Castiglione delle Stiviere, IT
Marco Ferrara · San Donato Milanese, IT
Giacomo Fossati · Lissone, IT
Scott Hobson · Mittelbiberach, DE
Uta Friederike Lessel · Maselheim, DE
Frank Runge · Biberach an der Riß, DE
Ursula Mueller-Vieira · Ingelheim am Rhein, DE
Julian Wippich · Ingelheim am Rhein, DE

Key dates

Filing date	Mar 29, 2021
Grant date	Oct 10, 2023
Priority date	—
Expiry date	Aug 18, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/00
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention relates to substituted 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) for use as a medicament, pharmaceutical compositions comprising the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.